Merkoša sitáhtat
APA-čujuhus (7. p.)
Phuensan, P., Sirimongkolkasem, J., Tantawichien, T., Phannajit, J., Kerr, S. J., Hansasuta, P., . . . Rerknimitr, R. (2024). Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines – A prospective multi-center study. Elsevier.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Chicago-čujuhus (17. p.)
Phuensan, Pawat, et al. Immunogenicity and Safety of Heterologous Versus Homologous Prime-boost Schedules with Inactivated and Adenoviral Vectored SARS-CoV-2 Vaccines – A Prospective Multi-center Study. Elsevier, 2024.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
MLA-čujuhus (9. p.)
Phuensan, Pawat, et al. Immunogenicity and Safety of Heterologous Versus Homologous Prime-boost Schedules with Inactivated and Adenoviral Vectored SARS-CoV-2 Vaccines – A Prospective Multi-center Study. Elsevier, 2024.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.